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model spending. We report adjusted relative risks (adjusted_RR) with 95% confi-
dence intervals (CIs) formultivariable logistic regressions and adjusted coefficients
with standard errors and p values for results from OLS models, controlling for
covariates. RESULTS: Inmultivariablemodels, COPDmaintenancemedication dis-
continuation increased hospitalization risk (RR 1.08, 95%CI 1.06, 1.10), while high
MPR reduced hospitalization risk (RR  0.93, 95% CI 0.91, 0.95) compared to low
MPR. Medication discontinuation also increased total spending by $2350 (p 
0.001), driven largely by Part A spending ($4039; p 0.001) and offset by Part D drug
spending reductions (-$1,833; p 0.001). High adherence significantly reduced total
spending by $4273 (p 0.001),whilemoderate adherence reduced spending by $936
(p  0.05) relative to poor adherence. CONCLUSIONS: Findings highlight the im-
portance of adhering to prescribed pharmacologic regimens of COPDmaintenance
medication in reducing hospitalizations and associated costs.
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OBJECTIVES: Isoniazid ishighly effectiveandwidelyused forTBpreventionand treat-
ment; however itmust be used consistently for 6 to 9months to treat latent TB,which
is usually asymptomatic. The combination of long-term therapy and lack of symp-
toms results in high risk for non-adherence. The cost of subsequent treatment for
patients with isoniazid resistance is estimated at $1million per reactivation case pre-
vented. These data highlight the need for more information about adherence with
isoniazid in patients with latent TB. The specific aim of this study was to document
adherence patterns in patients with latent TB and examine associations with patient
characteristics. We also examined patient’s attitudes toward intentional nonadher-
ence in relation tomedical doubts, lack of social support, andmedication side effects
by using the Temptation to Skip Therapy (TEST) scale. METHODS: Questionnaires
were completed at baseline by 211 isoniazid treated patients (aged 18-66) at the Rhode
IslandTuberculosis Clinic. Adherencewas subsequentlymeasured at 6 and 9months.
The average score was computed for each TEST subscale and the association with
each subscale and the Morisky Medication Adherence Scale (MAS) was examined.
RESULTS: Adherence to INH therapy was 45% (by MAS). Latent TB patients scored
highest on theSideEffect (Mean1.62) and lowest on theTESTMedicalDoubt subscale
(Mean  1.47). Non-Whites exhibited higher mean scores on the Medical Doubt sub-
scale indicating uncertainty toward the need for therapy. Patients with higher scores
on the Medical Doubt and Side Effect subscales had higher non-adherence levels.
CONCLUSIONS: Latent TB patients exhibited low adherence with isoniazid therapy.
Fear of side effects and doubts about the need for medication were related to discon-
tinuation of therapy. Better understanding of attitudes toward isoniazid therapymay
be beneficial for improving adherence, and reducing costs associated with isoniazid
treatment.
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OBJECTIVES: Physical functioning scales have been used to assess risk for disabil-
ity, propensity for healthcare utilization, and impact on quality of life (QOL) scores.
Understanding related factors in a nationally representative older population is
important for designing effective physical functioning improvement programs,
potentially decreasing utilization and increasing QOL.METHODS: To measure im-
pact of demographics, morbidities, psychological distress and lung function on
physical functioning among the retired, a retrospective main effects analysis of
data from the Health and Retirement Study (HRS) for subjects surveyed in 2006 and
2008 was performed on a sample of 13,129 patients aged 50 years (M  66.14;
45.9% male) with lung function measurement (peak expiratory flow (PEF)), and
psychological distress (symptoms of anxiety and depression) assessment (8 ques-
tion Center for Epidemiologic Studies Depression Scale (CES-D8)), and self-reported
confirmation of morbidity diagnoses. Morbidities were diabetes (19.4%), chronic
obstructive pulmonary disease (COPD) (9.8%), heart disease (23.6%), cancer (13.7%),
and stroke (6.0%). RESULTS: In a weighted multiple regression model of physical
function difficulty score, 49% of the variance was explained by analyzed variables.
In a weighted logistic regression model for difficulties with 4 physical functions
(max12), adjusted for age and race, odds were significantly higher for subjects
reporting morbidities of frequent pain (odds ratio range (ORR) 6.0-7.7), COPD (ORR
2.4-3.4), stroke (ORR 2.0-2.8), heart disease (ORR 1.6-1.9), or diabetes (ORR 1.7-2.2). In
addition, greater risk for physical function difficulties was associated with psycho-
logical distress (ORR 2.2-3.0) and low PEF scores (80% of predicted, ORR 1.7-2.1).
Among retirees with COPD, 59.3% had low PEF scores compared to 23.7% without;
34.8% had psychological distress compared to 19.6% without. CONCLUSIONS: The
secondary database of longitudinal data from the HRS offers valuable information
for understanding factors associated with functional limitations. Mental health
and lung functioning are potential areas for focusing improvement efforts.
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BACKGROUND: Patients with COPD have demonstrated poor adherence and persis-
tence with inhaledmaintenancemedications, suggesting low satisfaction with exist-
ing therapies. An understanding of the factors driving treatment satisfaction from the
patient perspective is necessary to develop or modify therapies to address patients’
concerns. OBJECTIVES: To examine factors influencing patients’ satisfaction with
COPD maintenance medications. METHODS: Fifty-two one-on-one semi-structured
telephone interviewswere conductedwithCOPDpatients to gather informationabout
attributes that influence satisfaction with COPD maintenance medication and deliv-
ery devices. Participantswere selected from two sources: patientswho recently exited
one of two trialswith aclidiniumbromide via theGenuair™ inhaler(n32) or non-trial
patients recruited from clinics who recently received treatment with tiotropium bro-
mide via the HandiHaler™(n20). A coding scheme for categorizing responses was
developed and interview transcripts were analyzed using qualitative software.
RESULTS: Focus group participants had amean age of 66.5 years; were 51.9% female;
andhadadiagnosis ofmoderate (GOLD II) to severe (GOLD III) COPD. Four components
of patients’ satisfaction were identified: ease of use/convenience, efficacy, onset of
action, and side effects. Regarding ease of use/convenience, patients most frequently
cited the importance of device portability (31%), device simplicity (27%), and whether
the device indicated that a dose had been received (25%). For efficacy, patients most
frequently mentioned whether the product made them feel that their airways were
open and they could catch their breath (42%), that the medication kept symptoms
from worsening (33%), and that the medication improved ambulatory ability (29%).
Nearly half of patients (46%) noted onset of action as important. Finally, thirty-five
percent of patients noted that side effects affected their satisfaction with treatment.
CONCLUSIONS: Ease of use/convenience, efficacy, onset of action, and side effects
drive patients’ satisfactionwith inhaled COPDmaintenancemedications. COPDmed-
ications and delivery devices that address these factors may improve patient adher-
ence and persistence.
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OBJECTIVES: Although respiratory symptoms are a defining feature of COPD, a
standardized method for assessing their day-to-day severity suitable for testing
treatment effects in clinical trials has not been established. This study examined
the reliability and validity of the E-RS (EXACT-Respiratory Symptoms), a respira-
tory symptom score derived from the 11 respiratory items of the 14-item EXACT, a
daily diary assessing exacerbations of COPD. METHODS: Content validity was as-
sessed through analyses of qualitative data from 84 patients with COPD, including
secondary analyses of data collected during EXACT development (n63) and data
from four new focus groups with patients without recent history of exacerbation
(n21). Quantitative properties were tested through secondary analyses of data
from 188 stable COPD patients gathered over 7 days during the first EXACT valida-
tion study. RESULTS: Qualitative: Sample mean (SD) age65(10), 44% male, mean
FEV11.2(0.4) L. Patient descriptions of respiratory symptoms during stable disease
were consistent with the E-RS content, wording, and structure. Quantitative: Sam-
plemean (SD) age66 (10), 50%male,mean FEV11.2(0.5) L. Factor analysis showed
three subscales: RS-Breathlessness (5 items), RS-Cough & Sputum (3 items) and
RS-Chest (3 items). For RS-Total and subscale scores, respectively: Reliability, in-
ternal consistency (alpha) 0.88 0.86, 0.73, 0.80; test-retest (ICC) Day 1 to 7 (n171)
0.73; 0.71; 0.69; 0.62. Validity: Correlations (Spearman’s) with St. George Respira-
tory Questionnaire – COPD (SGRQ-C) 0.75; 0.69, 0.58, 0.52, modified Medical Re-
search Council dyspnea scale (mMRC)0.33; 0.38, 0.24, 0.16, and rescuemedication
use 0.32; 0.34, 0.26, 0.17 (p0.05 to 0.0001). CONCLUSIONS: Results suggest the
E-RS is a valid and reliablemethod for evaluating severity of respiratory symptoms
in COPD; the daily diary structure permits assessment of day-to-day variability and
severity over time. Further research is needed to evaluate performance over longer
assessment periods and in response to treatment, and to refine score interpreta-
tion.
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OBJECTIVES: There is currently no validated tool to evaluate nighttime symptoms
in patients with COPD. The purpose of this study was to develop and test a patient
reported outcome (PRO) self-administered questionnaire for evaluating COPD
symptoms experienced during the night.METHODS: A review of the literature and
interviews with six clinical experts informed the development of a framework for
exploring patients’ experience with nighttime symptoms of COPD. Four focus
groups were conducted with twenty-seven subjects who experienced COPD symp-
toms at night or in the earlymorning. Trained interviewers used a semi-structured
interview guide, startingwith open ended questions. Grounded theorywas applied
using qualitative analysis software to identify key concepts and determine concept
saturation. A conceptual framework was developed to depict patients’ experience
with COPD symptoms at night. Items and response options were generated based
on the qualitative data. Subsequently, one-on-one cognitive debriefing interviews
were conducted with 10 COPD patients to assess item readability, comprehensive-
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